Evolving Clinical Paradigms for LDL Lowering - Focus on Efficacy, Implications, Side Effects, and Safety Results of Clinical Trials Evaluating PCSK9 Inhibition, APOB Suppression, and Other Novel Targets for Primary and Familial Hyperlipidemia - James M. McKenney, PharmD

Evolving Clinical Paradigms for LDL Lowering - Focus on Efficacy, Implications, Side Effects, and Safety Results of Clinical Trials Evaluating PCSK9 Inhibition, APOB Suppression, and Other Novel Targets for Primary and Familial Hyperlipidemia - James M. McKenney, PharmD


Published

October 29, 2015

Created by

CMEducation Resources symposium